Janssen pharmaceuticals xarelto?

Xarelto is rivaroxaban, a direct oral anticoagulant (DOAC) developed and marketed by Janssen Pharmaceuticals (Johnson & Johnson) in collaboration with Bayer. It inhibits Factor Xa to help prevent blood clots.

What it’s used for (common indications)
- Reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Prevention of DVT after hip or knee replacement surgery

Key points
- It’s taken as a fixed dose prescribed by a clinician; no routine blood monitoring like with warfarin is usually required, but kidney function, liver function, and potential drug interactions are important.
- Bleeding is the main risk. Report unusual bleeding, easy bruising, blood in urine/stool, severe headaches, or any signs of internal bleeding to a doctor.
- There are important drug interactions, especially with strong inhibitors or inducers of CYP3A4 and P-glycoprotein (P-gp). Tell your clinician about all meds, herbal supplements, and if you have kidney or liver problems.
- Not recommended in pregnancy; breastfeeding considerations apply. See the patient information or your doctor for details.

If you want, tell me which aspect you’re after (e.g., exact indications, dosing ranges, safety/side effects, or how it compares with other anticoagulants), and I can tailor the info.